Literature DB >> 32804304

Macrophage activation syndrome triggered by active systemic lupus erythematosus : Successful treatment by interleukin-1 inhibition (anakinra).

L Kübler1, I Bittmann2, J G Kuipers3.   

Abstract

This article presents a case of fulminant macrophage activation syndrome (MAS) as a rare complication of active systemic lupus erythematosus in a 33-year-old female patient. Initial presentation showed severe lupus disease exacerbation with renal involvement, hemolytic anemia, and neuropsychiatric changes. Early therapy focused on broad immunosuppression (high-dose corticosteroids and cyclophosphamide); however, disease remission could not be achieved. After an additional inflammatory focus and underlying malignancy were excluded, the triplet of pancytopenia, fever, and high ferritin levels indicated MAS, a bone marrow biopsy confirmed secondary hemophagocytic histiocytosis. Treatment with an interleukin‑1 antagonist (anakinra) induced a fast, effective therapeutic success.

Entities:  

Keywords:  Disease flare; Fever of unknown origin; Hyperferritinemia; Pancytopenia; Therapy resistance

Mesh:

Substances:

Year:  2020        PMID: 32804304     DOI: 10.1007/s00393-020-00836-w

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  3 in total

1.  Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance.

Authors:  Sofia Ajeganova; Ann De Becker; Rik Schots
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-11-24       Impact factor: 5.346

Review 2.  Macrophage Polarization and Plasticity in Systemic Lupus Erythematosus.

Authors:  Mariame Mohamed Ahamada; Yang Jia; Xiaochuan Wu
Journal:  Front Immunol       Date:  2021-12-20       Impact factor: 7.561

Review 3.  Crosstalk between Interleukin-1β and Type I Interferons Signaling in Autoinflammatory Diseases.

Authors:  Philippe Georgel
Journal:  Cells       Date:  2021-05-08       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.